Comprehensive Metabolomic Profiling in Urinary Bladder Cancer: Emerging Biomarkers for Early Diagnosis and Therapeutic Monitoring
- 10 March 2026
- journal article
- Published by Wiley in ChemistrySelect
- Vol. 11 (10)
Abstract
Urinary bladder cancer (UBCa) is a recurrent malignancy with a significant global health burden. Early and accurate detection is vital for improving outcomes. Metabolomics, the study of small molecules in biological systems, offers a powerful approach to reveal biochemical alterations in UBCa. Analysis of urine, tumor tissue, and blood highlights metabolic reprogramming, with mass spectrometry (MS) and nuclear magnetic resonance (NMR) as key profiling tools. Metabolites such as valine, tryptophan, taurine, uridine, and phosphocholine have emerged as potential biomarkers. Common alterations include reduced citrate and elevated lactic acid and fatty acids, reflecting dysregulated energy metabolism. The noninvasive nature of urine and blood sampling enhances clinical applicability. Overall, metabolomics provides valuable insights and a promising platform for early diagnosis and personalized therapy in UBCa.Keywords
This publication has 92 references indexed in Scilit:
- Recent Advances in Liquid Chromatography–Mass Spectrometry (LC–MS) Applications in Biological and Applied SciencesAnalytical Science Advances, 2025
- Green nanotech paradigm for enhancing sesquiterpene lactone therapeutics in cancerBiomedicine & Pharmacotherapy, 2024
- Metabolomics for the diagnosis of bladder cancer: A systematic reviewAsian Journal of Urology, 2023
- NMR-Based Metabolomics in Cancer Research2021
- Targeted metabolomics in bladder cancer: From analytical methods development and validation towards application to clinical samplesAnalytica Chimica Acta, 2018
- Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancerCancer Medicine, 2017
- The Strengths and Weaknesses of NMR Spectroscopy and Mass Spectrometry with Particular Focus on Metabolomics Research2015
- LC‐MS‐based serum metabolic profiling for genitourinary cancer classification and cancer type‐specific biomarker discoveryProteomics, 2012
- Mass spectrometry‐based metabolomicsMass Spectrometry Reviews, 2006
- Detection of Bladder Cancer Using a Point-of-Care Proteomic AssayJAMA, 2005